Achillion Pharmaceuticals (ACHN) Sell Rating Reiterated at Chardan Capital Markets Amid ACH-4471 Risks
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Chardan Capital Markets Upgrades Achillion Pharmaceuticals (ACHN) to Neutral Following Underperformance
November 4, 2016 6:33 AM EDTChardan Capital Markets upgraded Achillion Pharmaceuticals (NASDAQ: ACHN) from Sell to Neutral with a price target of $5.00 share price underperformance relative to the XBI in the past three and a half months. The upgrade come ahead of 1H17 clinical catalysts in the multiple ascending dose (MAD) study of ACH-4471.
Analyst Madhu Kumar commented, "Over the past three and a half months (from market close 13 July to market close 3 November),... More
Leerink Maintains Achillion Pharma (ACHN) at 'Market Perform'; Says MAD Study Questions Raised
November 3, 2016 11:55 AM EDTLeerink affirms Achillion Pharma (NASDAQ: ACHN) at Market Perform following Q3 results and update issued earlier Thursday.
The firm commented today: We believe today's stock weakness is related to caution due to ACHN's disclosure of two cases of liver enzyme elevations in the ongoing multiple ascending dose (MAD) Phase I study of ACH-4471. This update was mentioned... More
Buy Achillion Pharmaceuticals (ACHN) on Sell-Off - Baird
November 3, 2016 11:53 AM EDTBaird analyst Brian Skorney is telling clients to buy Achillion Pharmaceuticals (NASDAQ: ACHN) on today's sell-off. The firm reiterated an Outperform rating and price target of $10.
Skorney commented, "The market for biotech has completely broken down and with it, Achillion's... More
Achillion Pharma (ACHN) Announces Two Side Effects Observed in MAD Study
November 3, 2016 10:20 AM EDTAchillion Pharma (NASDAQ: ACHN) posted the following with its Q3 press release on Thursday:
Phase I Clinical... More
Achillion Pharma (ACHN) Reports Q3 Loss of $0.15
November 3, 2016 9:03 AM EDTAchillion Pharma (NASDAQ: ACHN) reported Q3 EPS of ($0.15), versus ($0.16) reported last year.
For earnings history and earnings-related data on Achillion Pharma (ACHN) click here.
... More